title: In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma.
abstract: Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPG), are the leading cause of cancer-related death in children. While it is clear that surgery (if possible), and radiotherapy are beneficial for treatment, the role of chemotherapy for these tumors is still unclear. Therefore, we performed an in vitro drug screen on primary glioma cells, including three DIPG cultures, to determine drug sensitivity of these tumours, without the possible confounding effect of insufficient drug delivery. This screen revealed a high in vitro cytotoxicity for melphalan, doxorubicine, mitoxantrone, and BCNU, and for the novel, targeted agents vandetanib and bortezomib in pHGG and DIPG cells. We subsequently determined the expression of the drug efflux transporters P-gp, BCRP1, and MRP1 in glioma cultures and their corresponding tumor tissues. Results indicate the presence of P-gp, MRP1 and BCRP1 in the tumor vasculature, and expression of MRP1 in the glioma cells themselves. Our results show that pediatric glioma and DIPG tumors per se are not resistant to chemotherapy. Treatment failure observed in clinical trials, may rather be contributed to the presence of drug efflux transporters that constitute a first line of drug resistance located at the blood-brain barrier or other resistance mechanism. As such, we suggest that alternative ways of drug delivery may offer new possibilities for the treatment of pediatric high-grade glioma patients, and DIPG in particular.
authors: Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands.
authors: Susanna J E
authors: SJ
authors: Veringa
authors: Dennis
authors: D
authors: Biesmans
authors: Dannis G
authors: DG
authors: van Vuurden
authors: Marc H A
authors: MH
authors: Jansen
authors: Laurine E
authors: LE
authors: Wedekind
authors: Ilona
authors: I
authors: Horsman
authors: Pieter
authors: P
authors: Wesseling
authors: William Peter
authors: WP
authors: Vandertop
authors: David P
authors: DP
authors: Noske
authors: GertJan J L
authors: GJ
authors: Kaspers
authors: Esther
authors: E
authors: Hulleman
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D020295:Brain Stem Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005910:Glioma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D060787:Neoplasm Grading
chemical_list: D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents
references: Oncologist. 2004;9(2):197-206
references: 15047924
references: Anticancer Res. 2006 Nov-Dec;26(6B):4499-503
references: 17201170
references: Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46
references: 19495754
references: Br J Cancer. 2001 Mar 2;84(5):604-10
references: 11237379
references: Neuropediatrics. 2008 Aug;39(4):211-8
references: 19165709
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: Clin Cancer Res. 2005 Nov 15;11(22):8145-57
references: 16299247
references: Clin Cancer Res. 2007 Mar 1;13(5):1516-22
references: 17332297
references: J Neurooncol. 1992 Sep;14(1):37-43
references: 1361524
references: Mol Ther. 2008 Mar;16(3):487-93
references: 18253154
references: Neurosurg Focus. 2003 Feb 15;14(2):e1
references: 15727422
references: Cancer Treat Rev. 2012 Feb;38(1):27-35
references: 21764221
references: Anticancer Drugs. 1999 Feb;10(2):179-85
references: 10211548
references: J Biomol Screen. 1999;4(2):67-73
references: 10838414
references: Proc Natl Acad Sci U S A. 1989 Jan;86(2):695-8
references: 2563168
references: Brain Pathol. 2003 Oct;13(4):482-94
references: 14655754
references: Mol Cancer Ther. 2004 Jun;3(6):737-45
references: 15210860
references: Int J Pharm. 2011 Nov 28;420(2):385-94
references: 21920419
references: Brain Tumor Pathol. 1999;16(1):23-7
references: 10532420
references: Bone Marrow Transplant. 1992 Aug;10(2):171-5
references: 1525606
references: J Med Chem. 1997 May 23;40(11):1726-30
references: 9171882
references: Biochem Pharmacol. 2003 Mar 1;65(5):765-71
references: 12628490
references: Pediatr Blood Cancer. 2012 Jul 15;59(1):27-33
references: 22162424
references: Science. 2007 Oct 12;318(5848):287-90
references: 17872411
references: Biochim Biophys Acta. 2002 Sep 20;1565(1):6-16
references: 12225847
references: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15665-70
references: 9861027
references: Cancer Chemother Pharmacol. 1994;33(6):477-83
references: 8137457
references: J Clin Neurosci. 2007 Mar;14(3):261-6
references: 17258135
references: Pediatr Int. 2003 Feb;45(1):74-9
references: 12654074
references: Cancer Res. 2006 Aug 15;66(16):7864-9
references: 16912159
references: J Neurooncol. 2010 Oct;100(1):95-103
references: 20213332
references: Cancer Res. 2006 Feb 15;66(4):2279-86
references: 16489032
references: Lancet Oncol. 2006 Mar;7(3):241-8
references: 16510333
references: Cancer Invest. 2006 Feb;24(1):77-81
references: 16466996
references: Br J Cancer. 1998 Sep;78(5):652-61
references: 9744506
references: Curr Drug Metab. 2010 Sep;11(7):603-17
references: 20812902
references: Cochrane Database Syst Rev. 2011 Mar 16;(3):CD007294
references: 21412902
references: J Pediatr Hematol Oncol. 2010 Jul;32(5):e202-6
references: 20523247
references: J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80
references: 16959960
references: Neuro Oncol. 2010 Feb;12(2):153-63
references: 20150382
references: J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
references: 10480340
references: Br J Neurosurg. 2011 Aug;25(4):459-69
references: 21344976
references: J Clin Oncol. 2010 Jun 20;28(18):3061-8
references: 20479398
references: Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):205-23
references: 18248313
references: Cancer Res. 2007 Nov 15;67(22):11012-20
references: 18006847
references: Melanoma Res. 2009 Jun;19(3):167-75
references: 19434004
references: Cancer Res. 2010 Oct 15;70(20):7981-91
references: 20876799
references: J Carcinog. 2010 Jul 14;9:
references: 20808823
references: Brain Res Brain Res Rev. 2001 Apr;35(2):161-204
references: 11336781
references: Clin Cancer Res. 2006 Aug 1;12(15):4523-32
references: 16899598
references: Curr Med Chem. 2010;17(12):1125-38
references: 20175745
references: Neuro Oncol. 2011 Apr;13(4):410-6
references: 21345842
references: Int J Cancer. 1992 Sep 9;52(2):241-6
references: 1355756
references: Lancet Oncol. 2002 Jul;3(7):397-406
references: 12142169
references: Oncotarget. 2011 Dec;2(12):984-96
references: 22184287
references: Curr Cancer Drug Targets. 2006 Aug;6(5):433-45
references: 16918310
references: Clin Neuropathol. 1997 Jan-Feb;16(1):34-6
references: 9020393
references: J Paediatr Child Health. 2011 Dec;47(12):875-82
references: 21658147
references: Cancer Res. 2001 Feb 15;61(4):1527-32
references: 11245461
references: Cancer Lett. 2007 Aug 28;254(1):11-29
references: 17275180
references: Neuro Oncol. 2009 Jun;11(3):274-80
references: 18981259
references: Neuro Oncol. 2011 Mar;13(3):317-23
references: 21339192
references: Cancer Chemother Pharmacol. 2002 Feb;49(2):133-41
references: 11862427
references: Clin Cancer Res. 2003 Feb;9(2):703-10
references: 12576438